Gabrielle joined as the CEO of Bioscript Group in 2022 with a passion for accelerating innovation across life sciences. She is a physician by background and moved into the pharmaceutical sector, from clinical practice, more than 20 years ago.

She has led both medical affairs and commercial teams at a global level specialising in neurology and psychiatry. Her career has also focused on the role of technology and companion diagnostics in delivering better patient outcomes. She led global marketing programmes for Alzheimer’s disease diagnostics as well as developing machine data software solutions in the field of anaesthesia.

Gaby has worked agency side as a Partner in corporate and financial communications across life sciences.

Her board level roles have focused on health and social care services businesses, the NHS and US speciality pharma, working on therapeutics in addiction.

Gaby’s role at Bioscript Group is to ensure that the teams bring the best of Bioscript scientific, regulatory and market access capability to our clients. In recognising the complexity of the development, approval and commercialisation ecosystem, she is committed to building long term strategic partnerships to allow innovative therapeutics to reach patients as quickly as possible.

With greater than 20 years’ experience in regulatory writing and clinical trial management, Jason Forward brings a wealth of technical and scientific experience to the group. As the Managing Director for Regulatory Writing, he is responsible for the development and implementation of strategic practices, rooted firmly in operational experience and high-quality delivery.

Jason is passionate about providing practical solutions that meet clients’ needs, enabling his team to work in a consultative capacity. In an ever-demanding environment, the health and wellbeing of staff are paramount, driving retention and long-term consistency of the support provided. With a fascination for the opportunities provided by digital transformation, Jason is working collaboratively to shape the services and capabilities on offer to clients, shortening the timelines of regulatory document delivery.

With over 20 years of leadership experience in the biopharmaceutical industry, Gerdi Strydom is a seasoned expert in market access strategy, pricing, and payer evidence development. Currently serving as the Managing Director at Valid Insight, Gerdi’s career has been defined by her ability to craft and execute integrated value and access strategies that drive the successful commercialisation and reimbursement of innovative therapies across diverse therapeutic areas, including oncology, immunology, rare diseases, and vaccines.

Gerdi’s strategic insights are deeply rooted in her extensive experience in both consulting and leading roles within major biopharmaceutical companies such as Pfizer and Roche. Her proven track record of translating complex market challenges into actionable strategies and effectively navigating product development, launch, and commercialisation processes globally, is a testament to her adaptability and strategic capabilities. Her leadership has spanned Europe, Asia, Latin America, Africa, and the Middle East, where she has managed intricate pricing negotiations to optimise product value.

Gerdi’s approach is underpinned by a steadfast commitment to ensuring that innovative therapies reach the patients who need them most. Her focus on maximising market potential and aligning with payer expectations underscores her strategic approach and dedication to the industry.

Dave Andrews is an academic scientist who took his love of talking about science and turned it into a professional career. Dave has a depth of experience from having been an academic scientist, a medical writer, a business owner and has worked in both agencies supporting the pharma and biotech industries as well as within industry. Dave’s experience spans multiple therapeutic areas, developing communications strategies for molecules from early phase through the development and commercialisation phases.

Dave’s role as Chief Scientific Officer encompasses scientific strategy and development of programmes of communication that can span multiple years, putting together multichannel approaches to data dissemination and identifying novel approaches to communicating science.

James has a wealth of experience having spent 10 years at KPMG Corporate Finance where he advised on approaching £1bn of transactions. Having moved into industry, James has worked at board level, bringing strategic, commercial leadership and insight across Operations and Finance. With his Corporate Finance background, James brings a detailed knowledge and expertise in Mergers and Acquisitions (M&A).

At Bioscript Group, James’s role is to bring a commercial and financial oversight into operations as well as driving the strategic direction of the business with the board.

Kim is a commercially-focussed, practice trained accountant with over 15 years’ experience in finance. Her expertise includes acquisitions and business change in Service businesses.
Having built new teams and systems within startup businesses and managed group finance functions in large international organisations, Kim has experience across a wide range of business environments. She is solutions driven with a focus on data improvement and enhancement of cross-departmental collaboration within the business. Previously CFO of a regulated business, she has an analytical approach and a keen understanding of data.
Kim’s main focus at Bioscript Group is to support the business through change and growth, maximising reporting capabilities and ensuring collaboration throughout the teams.

Mark Christie is a seasoned Chief Information Officer with over 30 years of experience in technology transformations. His expertise includes IT-enabled business change, project delivery, and IT solutions aligned with business strategies. His expertise in Mergers and Acquisitions (M&A) is notable, having successfully completed numerous acquisitions and divestments. Mark’s passion for technology in health and life sciences drives his focus on improving lives through the use of technology.

He has led IT strategy alignment with business goals, managed significant IT budgets, and spearheaded diverse IT functions. His leadership in implementing technology solutions has supported critical business transformations, reflecting his commitment to service improvement and excellence.

Mark’s role at Bioscript Group extends beyond IT, encompassing digital transformation, change management, data insights, and Environment, Social and Governance (ESG). His strategic vision for technology within the group is shaping the future of digital services and capabilities across Bioscript Group.

Eleri is a commercially driven Human Resources leader with over 20 years global HR experience. She has worked both in the US and UK and has been responsible for driving the people agenda within international, fast paced, culturally diverse and change driven environments. Her industry experience includes Telecommunications, Healthcare and Private Equity backed technology organisations. A board level leader, she has experience of working in a range of different sectors within single and multisite SMEs to large, complex organisations with employee numbers ranging from 60 – 1500. Eleri has significant experience in Mergers and Acquisitions (M&A), Organisation Design and Restructures, Operational Strategy, Employee Value Proposition and Talent Acquisition.

Here at Bioscript Group, Eleri is responsible for all HR and Talent Acquisition activities. Supporting all teams across the organisation, her main areas of focus include Employee Engagement, Organisational Development, Talent Acquisition, Employee Development and partnering with all leaders to foster a high-performing culture.